ITIşık Tekin

Işık Tekin

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Işık Tekin has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Levels of ER Stress Markers GRP78, CHOP, and PERK in Cardiovascular Diseases

    by Tülay Oskay, Alten Oskay, Mert Özen, Isık Tekin, Fırat Okta, Abdo A. Elfiky, Murat Seyit, Atakan Yılmaz, Hakan Akça, Ibrahim Türkçüer, et al.

    Cardiovascular diseases remain the leading cause of mortality worldwide, and endoplasmic reticulum (ER) stress has emerged as an important molecular mechanism underlying myocardial injury and heart failure. This study investigated the expression of the ER stress-related genes GRP78, PERK, and CHOP in peripheral whole blood obtained from patients with acute cardiovascular diseases. A total of 300 participants were enrolled, including 200 patients with ST-segment elevation myocardial infarction (STEMI, n = 55), non-ST-segment elevation myocardial infarction (NSTEMI, n = 88), decompensated heart failure (DHF, n = 40), or unstable angina pectoris (USAP, n = 17), and 100 healthy controls. Relative mRNA expression levels were quantified using quantitative real-time PCR. Intergroup comparisons were performed using the Kruskal–Wallis test followed by Dunn’s post hoc test with Bonferroni adjustment. Significant differences in GRP78, PERK, and CHOP expression were observed among the study groups (all p < 0.001). GRP78 and PERK expression levels were highest in the STEMI and DHF groups, whereas CHOP expression was highest in the STEMI group. Significant positive correlations were identified between troponin and CHOP (r = 0.48), GRP78 (r = 0.42), and PERK (r = 0.39) (all p < 0.001), while weaker but significant associations were observed between inflammatory markers (CRP and NLR) and ER stress-related gene expression. Exploratory receiver operating characteristic (ROC) analysis showed that CHOP demonstrated the highest discriminatory performance for distinguishing patients with acute cardiovascular disease from healthy controls. These findings indicate that peripheral whole-blood ER stress-related gene expression is associated with acute cardiovascular disease and correlates with established biomarkers of myocardial injury and inflammation. Further prospective studies are required to determine the clinical significance of these findings.

  • Open Access

    CYP450 Metabolizer Phenotypes in a Turkish Emergency Cardiac Patient Cohort: A Descriptive Pharmacogenomic Study

    by Alten Oskay, Tülay Oskay, Veli Kaan Aydın, Özer Eser, Murat Seyit, Işık Tekin, Mert Özen, Atakan Yılmaz, İbrahim Türkçüer, Gergana Lengerova, et al.

    Background/Objectives: Cytochrome P450 enzymes (CYP2D6, CYP2C19, CYP3A4) play a key role in interindividual variability in cardiovascular drug metabolism. This study aimed to describe metabolizer phenotype distributions in a Turkish emergency cardiac cohort and across diagnostic categories. Methods: This retrospective descriptive pharmacogenomic study included 250 patients. Genotyping was performed using TaqMan assays for CYP2D6 (*2, *4, *10, *41), CYP2C19 (*2, *17), and CYP3A4 (*22, *1B). Phenotypes were assigned according to CPIC guidelines. CYP2D6 copy-number variation was not assessed. Results: Non-normal metabolizer phenotypes were observed in 55.6% (CYP2D6), 84.4% (CYP2C19), and 30.4% (CYP3A4) of patients. For CYP2D6, normal (44.4%) and intermediate (42.0%) metabolizers predominated. For CYP2C19, intermediate metabolizers were most frequent (36.0%), followed by normal (22.8%), rapid (17.2%), poor (14.8%), and ultra-rapid metabolizers (9.2%). CYP3A4 showed predominantly normal activity (69.6%). Phenotype distributions varied across diagnoses without clear clustering. Conclusions: A high prevalence of CYP2D6 and CYP2C19 variability with predicted functional relevance based on CPIC was observed, whereas CYP3A4 activity was more stable. These findings provide descriptive pharmacogenomic data to support future genotype-guided cardiovascular therapy studies.


  • Open Access

    State-Dependent DNA Methylation Signatures Distinguish Acute from Stable Coronary Syndromes

    by Işık Tekin, Alten Oskay, Tülay Oskay, Murat Seyit, Mert Özen, Atakan Yılmaz, Yasemin Berberoğlu, Abdo A. Elfiky, Gergana Lengerova, Martina Bozhkova, et al.

    Coronary artery disease presents heterogeneous clinical manifestations ranging from stable coronary syndrome (SCS) to acute coronary syndrome (ACS). Epigenetic mechanisms, particularly DNA methylation, may contribute to both chronic disease progression and acute plaque destabilization. However, genome-wide methylation differences between ACS, SCS, and healthy individuals remain incompletely characterized. Genome-wide DNA methylation analysis was performed in patients with ACS, patients with SCS, and healthy controls using pairwise comparisons (ACS vs. control, SCS vs. control, and ACS vs. SCS). Differentially methylated regions were identified using logistic regression implemented in the methylKit package in R. Regions with a false discovery rate-adjusted q-value < 0.05 and an absolute methylation difference (|Δβ|) > 20% were considered significant. Unsupervised hierarchical clustering revealed clear separation between ACS, SCS, and control samples, indicating distinct epigenetic profiles. ACS showed the most pronounced methylation alterations compared to controls, whereas SCS exhibited more moderate changes consistent with chronic epigenetic remodeling. Direct comparison between ACS and SCS identified dynamic, state-dependent methylation differences. Pathway analysis demonstrated enrichment of stress response, apoptotic signaling, and cell adhesion pathways in ACS, while SCS was primarily associated with pathways related to intercellular communication and vascular signaling. Our findings demonstrate that acute and stable coronary syndromes are characterized by distinct DNA methylation landscapes and pathway signatures. Epigenetic regulation of stress, adhesion, and signaling pathways may contribute to disease acuity and progression, highlighting DNA methylation as a potential molecular marker in coronary artery disease.


  • Türkiye Genelinde Transtiretin Kardiyak Amiloidozlu Hastalarda Tanı ve Tedavi Süreçlerinin Çok Merkezli Retrospektif Analizi

    by Işık Tekin, Yalın Tolga Yaylalı, Cafer Zorkun, Pelin Karaca Özer, Sadık Volkan Emren, Belma Kalaycı, Mehdi Zoghi

    Amaç: Transtiretin kardiyak amiloidoz (ATTR), sıklıkla tanıda gecikmelerin yaşandığı, multisistemik tutulum gösteren ve prognozu ciddi bir hastalıktır. Bu çalışmada, Türkiye’de üçüncü basamak merkezlerde tanı alan ATTR olgularının klinik, tanısal ve tedaviye yönelik özelliklerinin değerlendirilmesi amaçlanmıştır.Yöntem: Ocak 2015 – Aralık 2023 yılları arasında yedi merkezde transtiretin kardiyak amiloidoz tanısı almış 38 hasta retrospektif olarak incelendi. Demografik veriler, başvuru şikâyetleri, laboratuvar ve görüntüleme bulguları, kırmızı bayrak özellikleri, tanı yöntemleri ve farmakolojik tedavi yaklaşımları analiz edildi.Bulgular: Çalışmaya dâhil edilen hastaların ortalama yaşı 59,3±12,9 yıl olup %57,9’u erkekti. En sık başvuru yakınması halsizlikti (%78,9). Kırmızı bayrak özellikleri arasında periferik nöropati (%61,1), ortostatik hipotansiyon (%44,4) ve gastrointestinal yakınmalar (%37,1) ön plandaydı. Kardiyak değerlendirmelerde düşük voltajlı EKG (%54,1), granüler sparkling (%54,1) ve ileri diyastolik disfonksiyon (%39,5) sık görüldü. PYP sintigrafisinde Grade 2–3 tutulumu %92,1 hastada saptandı. Genetik analizlerde %55 ATTRv, %15 ATTRwt, %30 negatif sonuç elde edildi. Tafamidis kullanan hastalarda kalp yetersizliği bulguları (p=0,022) ve proteinüri (p=0,007) anlamlı derecede daha yüksek oranda izlendi.Sonuç: Türkiye’de ATTR olguları beklenenden daha genç yaşta ve herediter formların baskın olduğu bir klinik spektrumla karşımıza çıkmaktadır. Kırmızı bayrak bulgularının yüksek oranlarda görülmesi, tanı sürecinde multidisipliner yaklaşımın önemini ortaya koymaktadır. PYP sintigrafisinin biyopsi ihtiyacını azalttığı görülmüş olup, tafamidis tedavisinin daha ağır seyirli olgularda tercih edildiği anlaşılmaktadır. Bu sonuçlar, ulusal düzeyde tanısal farkındalık ve tedaviye erişimin artırılmasının önemini vurgulamaktadır.

  • Open Access

    Endothelial stress indices in acute coronary syndrome: comparative prognostic performance of EASIX and its variants

    by Işık Tekin, İpEk Büber, Esin Avcı

    Objectives: Endothelial dysfunction plays a pivotal role in the pathophysiology of acute coronary syndromes (ACS), contributing to vascular instability and impaired perfusion. The endothelial activation and stress index (EASIX), originally developed for hematologic conditions as a marker of endothelial stress, has recently attracted interest in cardiovascular prognostication. However, its utility in ACS remains insufficiently defined. This study aimed to evaluate the prognostic performance of the original EASIX and its simplified (s-EASIX) and modified (m-EASIX) variants in predicting 30-day in-hospital mortality in ACS patients. Methods: We retrospectively analyzed 368 patients with ACS admitted to a coronary intensive care unit between June 2022 and June 2024. EASIX-based scores were calculated from admission laboratory parameters. The primary endpoint was all-cause in-hospital mortality, defined as death occurring during hospitalization or within 30 days of admission. Predictive accuracy was assessed using receiver operating characteristic (ROC) curve analysis, multivariate Cox regression, and model fit via Akaike information criterion (AIC). Results: In-hospital mortality occurred in 19 patients (5.2 %). All three scores were significantly higher among non-survivors (p<0.01). m-EASIX demonstrated the highest AUC (0.818) and sensitivity (88.2 %), followed by EASIX (AUC: 0.789) and s-EASIX (AUC: 0.709). In multivariate Cox analysis adjusted for conventional clinical variables, all scores independently predicted mortality, with s-EASIX yielding the highest hazard ratio (HR=2.149; p<0.01). EASIX achieved the best model fit (AIC=123.123). Conclusions: EASIX and its variants are independent predictors of short-term mortality in ACS. Among them, the original EASIX exhibited the most consistent overall performance, supporting its potential role in early risk stratification of critically ill cardiac patients.


  • Open Access

    Association of UGT1A9 Polymorphisms with Cardiac Injury Biomarkers and Clinical Features

    by Mert Özen, Işık Tekin, Abdo A. Elfiky, Murat Seyit, Yasemin Adalı, Yasemin Berberoğlu, Alten Oskay, Atakan Yılmaz, Tülay Oskay, Vefa Çakmak, et al.

    Background/Objectives: This study evaluates the relationship between UGT1A9 polymorphisms, cardiac biomarker patterns, and clinical presentations in patients admitted to the Pamukkale University Emergency Department with cardiac symptoms. Methods: A total of 207 consecutive patients presenting with chest pain, dyspnea, palpitations, or other cardiac complaints were initially enrolled. Patients with incomplete clinical data or unsuccessful genotyping were excluded prior to analysis, and all remaining samples were included in the final evaluation. UGT1A9 *1, *2, and *3 alleles were genotyped using allele-specific PCR and TaqMan® assays. Patients were classified into wt/wt, wt/*3, and *3/*3 groups. Statistical analyses included Kruskal–Wallis, Mann–Whitney U, and chi-square tests. Results: Genotype distribution was 64% wt/wt, 32% wt/*3, and 4% *3/*3. CK-MB levels differed significantly across genotypes (p = 0.006), with the highest in wt/*3 carriers. Troponin I levels showed no genotypic differences (p = 0.533). UGT1A9*3 carriers exhibited elevated CK-MB with relatively low Troponin I, suggesting possible statin-associated muscle injury rather than true myocardial necrosis. Conclusions: UGT1A9 polymorphisms, particularly UGT1A9*3, influence CK-MB variability and may confound the assessment of myocardial injury. Troponin I remains unaffected by genotype. Incorporating UGT1A9 pharmacogenetic testing may contribute to a better understanding of biomarker variability and support future research toward personalized therapeutic strategies.